Are memantine, methylphenidate and donepezil effective in sparing cognitive functioning after brain irradiation?  

作　　者：Rosa Wartena Dieta Brandsma Jose Belderbos 

机构地区：[1]Amsterdam Universitair Medische Centra,Amsterdam 1081HV,The Netherlands [2]Department of Neuro-oncology,The Netherlands Cancer Institute,Amsterdam 1066CX,The Netherlands [3]Department of Radiation Therapy,The Netherlands Cancer Institute,Amsterdam 1066CX,The Netherlands

出　　处：《Journal of Cancer Metastasis and Treatment》2018年第1期694-701,共8页癌症转移与治疗（英文版）

摘　　要：One strategy to reduce neurocognitive deterioration in patients after brain irradiation is the use of neuroprotective medication.To generate up-to date knowledge regarding neuroprotective agents we performed a systematic review on the clinical effectiveness of three agents that were reported to have neuroprotective characteristics:memantine,methylphenidate and donepezil.The use of memantine after brain irradiation showed a delay in cognitive deterioration,although at 24 weeks this did not reach significance(P=0.059).Lack of significance is likely to be the result of the limited statistical power of 35%and memantine did show significant differences in secondary outcomes.The study on methylphenidate was not conclusive.Donepezil revealed significant differences in a few cognitive tests however no difference in global cognition was found.In addition,larger effects were observed in individuals with greater cognitive dysfunction prior to treatment.

关 键 词：MEMANTINE DONEPEZIL METHYLPHENIDATE brain irradiation NEUROPROTECTION whole brain irradiation neuroprotective agent lung cancer 

分 类 号：R73[医药卫生—肿瘤]